Ann: Successful Completion of Key Translational Milestone, page-36

In August this was shared with shareholders:
Engage with US capital markets and drive business and corporate development

Engagement with the world's leading business development partners and life science investors to establish the Company as a global leader in Ribonucleic Acid (RNA) therapeMembers of PYC’s management team will also participate in one-on-one meetings with U.S biotech and life science investors.utics. The Company anticipates these engagements will create meaningful opportunities to more quickly progress and expand the Company's science and development programs.

Expanded application of the Company's PPMO technology to the CNS after demonstrating successful delivery of high levels of RNA therapeutic in mouse brains. Company remains on-track to nominate a first CNS development program in 2H 2021.

In September:
Members of PYC’s management team will also participate in one-on-one meetings with U.S biotech and life science investors.


....and then it all falls silent, while the good news keep coming in regards to second ocular pipeline, rabbit retina penetration and now monkey tox data.
All excellent, clear milestones, while price is not moving, but churn is ongoing, stacking, wiping and followed by suppression, as could be seen today and since end August.

Typical TO scenario, in our case licence deals, as I see it.



Join those dots together of corporate activity in the US, the fact that both, Haddock and Rosenblatt are due for re-election to our board ( in my view they were the ones conducting those one on ones during the Oppenheimer Summit ), and our ongoing research data achievements and one will soon come to the conclusion that something similar to Voyager is unfolding here, which was long held low ( at a 64% loss, sounds familiar Linsanity? Do those numbers of our gap correlate? ) prior to the Pfizer licence deal uptake.


Such is the biotech game, one needs to identify the milestones, trading patterns and join the events to attempt to anticipate massive market moving developments once deals are pronounced.

all IMO